Research platform
Research platform of Noxi Lab allows generating original hybrid molecules from endogenous bioregulators, pharmacologically active compounds and nitric oxide donors (NO-donors)
Main News
* Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma * Gurus raises $0.8M for preclinical trials of a drug for correction of cognitive disorders

For Investors

Collaboration with investors
Gurus invites both private and institutional investors to co-invest with us in development of innovative drugs, that is one of the most promising industries in the world, dynamically developing in Russia having a strong support at the government level. It can be more interesting alternative than investing money in shares of the old resource-based economy.
We offer an opportunity to co-invest both in selected drug development project and in a diversified portfolio of biopharmaceutical projects.

Investment Approach
By investing in innovative start-up, the investor gives a chance to be born for a new product or technology, and thus contributes to the development of civilization and progress. In addition to income, the investor links his name with a discovery that changes the world.
By investing in the "blue chip" stocks or long-established public companies the investor, in fact, buys shares from the previous investor on the secondary securities market. This deal only redistributes the margin between the old investor and the new one, but neither raises a capital for the issuing company, nor creates a new product or new technology and therefore does not lead to progress.
Of course, the primary and secondary securities markets cannot exist without each other, as the secondary market is needed to maintain the liquidity of the shares. Nevertheless, some investments build the progress, some investments don’t.
Drug development is a long-term process, which assumes a long-term alliance of investors, scientists and management team. We are developing collaboration with investors who share our values.

Selection of projects
Unlike most funds, we are not looking for projects with minimal risk or that are well-prepared to invest. Projects with some technological incompleteness do not confuse us, if they have considerable innovative potential. Gurus has expertise and technological capabilities to eliminate the shortcomings of the project and to unlock its potential.

Our differences
Unlike traditional venture funds, we conduct scientific research as a part of our business, so we have the opportunity to enter into the project before the funds at a scientific research stage, selecting the best projects for our investors.
Gurus is one of the few companies that provides for private investors an opportunity to co-invest in development of innovative drugs.

Investment stage
Gurus enters the project earlier than venture fund, as a rule, at the stage of the first encouraging experimental results on the pharmacological activity and toxicology.
Further, we start to prepare the project for the start of preclinical studies, providing additional experiments and strengthening intellectual property protection. Not all projects coming to us initially have adequate patent protection. In some cases, we can start project development from the very beginning, since the stage of generating an attractive idea for the new drug.